Potassium Chloride
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Potassium Chloride: From Potassium Deficiency to Renal Tubular Acidosis
One-Sentence Summary
Potassium chloride is a potassium replacement originally used to treat potassium deficiency and constipation disorder. The TxGNN model predicts it may be useful for renal tubular acidosis, but there are no registered clinical trials and the literature is mostly case reports and reviews. Any benefit is likely supportive (correcting low potassium) rather than a treatment of the underlying disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Potassium deficiency disease; constipation disorder |
| Predicted New Indication | Renal tubular acidosis |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L4 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, potassium chloride is an electrolyte replacement, its use in potassium deficiency is well established, and it may be applicable to renal tubular acidosis through potassium repletion.
Distal renal tubular acidosis (dRTA) commonly causes urinary potassium loss and low blood potassium (hypokalaemia). Potassium replacement therefore addresses a real clinical consequence of the disease. The very high TxGNN score most likely reflects this established link between potassium deficiency and renal tubular acidosis, rather than a new repurposing mechanism. The original indication (potassium deficiency) already overlaps with this use.
Potassium replacement does not correct the underlying acid-base defect, which is managed mainly with alkali therapy such as bicarbonate or citrate. Potassium chloride may also be less suitable than potassium citrate in acidotic patients, because chloride does not correct acidosis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The compiled literature is mostly case reports and narrative reviews, with no RCTs. Several reports describe patients with RTA or hypokalaemic paralysis treated with potassium chloride. Two items are not relevant to this question (a veterinary hyperkalaemia review and a literary-medical commentary).
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 786013 | 1976 | Review | Am J Med Sci | Causes, consequences and correction of hypokalaemia |
| 6277192 | 1982 | Review | Am J Med | Review of distal nephron function disorders |
| 40288831 | 2025 | Case report with review | Nefrologia | Primary RTA in pregnancy; no systematic data on perinatal outcomes |
| 34748193 | 2022 | Case report | J Nephrol | Distal RTA with hypokalaemic periodic paralysis during pregnancy |
| 37727491 | 2023 | Case report | World J Clin Cases | Incomplete distal RTA uncovered during pregnancy |
| 38445406 | 2023 | Cohort/Genetic study | La Tunisie Medicale | Genotype-phenotype correlation of dRTA; hypokalaemia and nephrocalcinosis features |
| 34595212 | 2021 | Case report | Case Rep Nephrol Dial | RTA type I with severe hypokalaemia (1.6 mEq/L) in Sjögren’s/lupus; treated with potassium chloride infusion |
| 40654398 | 2024 | Case report | JNMA | Sjögren’s syndrome presenting with severe hypokalaemia; treated with intravenous potassium chloride |
| 25447623 | 2015 | Prospective analysis | Am J Med | Causes and treatment of hypokalaemic nonperiodic paralysis |
India Market Information
The approved indication text is not listed for these registrations. Twenty single-ingredient registrations are valid; the main ones are shown below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 744 | Addkay Tablet PR | Strip of 10 prolonged-release tablets | Not listed |
| 179696 | Pegxit Oral Solution | Bottle of 200 ml oral solution | Not listed |
| 119005 | K-Lot Oral Solution | Bottle of 200 ml oral solution | Not listed |
| 174341 | Potcl 1.5gm Injection | Vial of 10 ml injection | Not listed |
| 115671 | Kcl Injection | Vial of 10 ml injection | Not listed |
Safety Considerations
- Disease associations flagged as contraindication-related (from the knowledge graph, not label text): kidney disease, anuria, hypertension, congestive heart failure, heart disease, coronary artery disease, liver disease, peptic or gastric ulcer, pancreatitis, and hypercalcaemia, among others. These should be checked against the package insert.
- Drug Interactions: 548 interactions were identified. Major ones include potassium-sparing or renin-angiotensin agents (amiloride, benazepril, olmesartan, valsartan, azilsartan), which raise the risk of hyperkalaemia, and anticholinergic or antihistamine agents (atropine, hyoscyamine, glycopyrronium, benzatropine, biperiden, amitriptyline, chlorpheniramine, brompheniramine, acrivastine). Moderate interactions include ketorolac, ibuprofen and aliskiren.
Please refer to the package insert for key warnings and formal contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score mainly reflects the known link between RTA and hypokalaemia. Evidence is limited to case reports and reviews with no clinical trials, and potassium chloride is supportive therapy rather than a treatment for RTA. Package insert safety data is also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Indian regulator’s sources
- Mechanism of action data
- Comparative evidence versus potassium citrate or alkali therapy in RTA
- Clinical studies on potassium replacement in RTA-related hypokalaemia
- A monitoring plan for serum potassium and renal function, given the major hyperkalaemia-related interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.